Core Insights - The Beijing Stock Exchange (BSE) has experienced a strong start in 2026, with a rapid pace of IPO approvals and listings, marking a significant expansion in high-quality companies [1] - As of January 30, 2026, the BSE has listed five new companies, bringing the total number of listed companies to 292, with a total market capitalization nearing 1 trillion yuan [1] Company Performance - **Kema Materials**: Listed on January 16, 2026, with a strong debut, seeing its stock price rise by 371.27% to close at 54.95 yuan per share, after peaking at a 585% increase [2] - **Aishalon**: Focused on medical health products, Aishalon's stock rose by 175.59% on its first day of trading, closing at 44.04 yuan per share [4] - **Guoliang New Materials**: Listed on January 22, 2026, with a stock price increase of 160.78%, closing at 28.06 yuan per share [6] - **Nongda Technology**: Officially listed on January 28, 2026, with a closing price of 52.89 yuan per share, reflecting a 111.56% increase from its opening price [7] - **Meidele**: Listed on January 30, 2026, with a significant opening price of 135 yuan per share, marking a 222.35% increase at the start of trading [7] Market Activity - The enthusiasm for new stock offerings has surged, with the total frozen funds for the five new IPOs exceeding 8 billion yuan each, and Meidele alone reaching approximately 1.06 trillion yuan, a record high for the BSE [9] - The average amount of funds frozen for new stock subscriptions has risen to 910 billion yuan, indicating strong investor interest [9] Roadshow Focus - All five newly listed companies conducted their online roadshows through a platform called "Panorama," emphasizing the importance of effective communication with investors [10]

Core Insights - The Beijing Stock Exchange (BSE) is becoming a significant platform for innovative small and medium-sized enterprises, with 290 listed companies and a total market capitalization nearing 1 trillion yuan as of January 23, 2026 [1][4] Group 1: Recent Listings - Three companies have recently gone public on the BSE: Kema Materials, Aisheren, and Guoliang New Materials, all of which have shown strong stock performance post-listing [2][3] - Kema Materials, specializing in dry and wet friction plates, saw its stock price surge by 371.27% on its first trading day, closing at 54.95 yuan per share [2] - Aisheren, focused on medical health products, experienced a 175.59% increase in its stock price, closing at 44.04 yuan per share on its debut [2] - Guoliang New Materials, a leader in refractory materials, had a first-day stock price increase of 160.78%, closing at 28.06 yuan per share [3] Group 2: Investor Participation - Investor enthusiasm for new stock offerings remains high, with over 800 billion yuan frozen for the three new listings, resulting in low allocation rates of 0.02%-0.03% [4] - Kema Materials attracted 855.76 billion yuan in frozen funds with a subscription rate of 0.026%, while Aisheren had 878.92 billion yuan with a rate of 0.028%, and Guoliang New Materials saw 828.08 billion yuan with a rate of 0.021% [4] - The upcoming IPOs of Nongda Technology and Medela are expected to draw significant investment, with Nongda Technology's recent offering seeing 9.29 billion yuan frozen and a subscription multiple of 2582.89 times [4] Group 3: Regulatory Environment - The frequency of IPO review meetings at the BSE has significantly increased since Q4 2025, focusing on nurturing specialized and innovative hard-tech enterprises [4] - In the week of January 19-23, the BSE's listing committee held three review meetings, successfully approving three companies: Bairuiji, Mifutech, and Toptech [4] - The enhanced review efficiency and improved market ecology position the BSE as a core channel for innovative enterprises to connect with capital markets [4]

Core Insights - The Beijing Stock Exchange (BSE) is becoming a significant platform for innovative small and medium-sized enterprises, with 290 listed companies and a total market capitalization nearing 1 trillion yuan as of January 23, 2026 [1] - The IPO review process on the BSE is maintaining a high frequency, with expectations for continued rapid issuance of new listings due to ongoing market reforms [1] Group 1: Recent Listings - Three companies have recently gone public on the BSE: Kema Materials, Aisheren, and Guoliang New Materials, all of which have shown strong stock performance post-listing [1][2] - Kema Materials, listed on January 16, 2026, saw its stock price surge by 585% at one point, closing at 54.95 yuan per share, a 371.27% increase from its issue price [1] - Aisheren, which focuses on medical health products, listed on January 21, 2026, and its stock rose by 175.59% to close at 44.04 yuan per share [2] - Guoliang New Materials, listed on January 22, 2026, experienced a stock price increase of 160.78%, closing at 28.06 yuan per share [2] Group 2: Investor Participation - Investor enthusiasm for new stock offerings is high, with over 800 billion yuan in frozen funds for the three new listings, resulting in low allocation rates of 0.02% to 0.03% [3] - Kema Materials attracted 855.77 billion yuan in frozen funds with a subscription rate of 0.026%, while Aisheren had 878.92 billion yuan with a rate of 0.028%, and Guoliang New Materials saw 828.08 billion yuan with a rate of 0.021% [3] - The upcoming IPOs of Nongda Technology and Medela are expected to draw even more investment, with Nongda Technology's recent offering resulting in 9.29 billion yuan in frozen funds and a subscription multiple of 2582.89 times [3] Group 3: Regulatory Environment - The frequency of IPO review meetings on the BSE has significantly increased since Q4 2025, focusing on nurturing specialized and innovative technology enterprises [3] - In the week of January 19-23, 2026, the BSE's listing committee held three review meetings, successfully approving three companies: Bairuiji, Mifutech, and Toptech [3] - The enhanced review efficiency and improved market ecosystem position the BSE as a key channel for innovative enterprises to connect with capital markets [3]

Core Insights - Aishalon officially listed on the Beijing Stock Exchange on January 21, marking a new chapter in its capital market journey [1] - The company, established in 2015, focuses on the research, production, and sales of disposable medical consumables in rehabilitation care and medical protection [1] Group 1: Business Model and Partnerships - Aishalon specializes in disposable medical consumables such as medical nursing pads and surgical drapes, primarily through ODM/OEM models for international medical device brands [2] - The company has established long-term strategic partnerships with notable brands including Medline Group (USA), Zarys Group (Poland), and Sejong Healthcare (South Korea) [2] - The chairman highlighted that the company has maintained relationships with core clients for over ten years, contributing to stable performance despite high customer concentration [2] Group 2: Innovation and R&D - As of the signing date of the prospectus, Aishalon holds 77 patents, including 21 invention patents, with a continuous increase in R&D investment focused on product performance upgrades and new product development [3] - The company plans to gradually develop its own brand while maintaining its ODM/OEM foundation, aiming for higher market value [3] Group 3: Future Growth and Strategy - The successful issuance and subsequent fundraising will allow Aishalon to expand existing production capacity and increase R&D investment in new medical consumables [4] - The company aims to transition from a single dressing manufacturer to a broader medical consumables manufacturing and service platform, reducing dependency on single products and clients [4] - Aishalon is establishing a global production footprint with a core domestic base and new facilities in Thailand and Morocco, demonstrating strategic vision to adapt to international trade changes and cost pressures [4]

Core Viewpoint - Aishalon Medical Technology Group Co., Ltd. successfully went public on the Beijing Stock Exchange, marking it as the first new A-share listed company in Jiangsu Province and Suzhou City in 2026, with a focus on stable operational and financial foundations rather than high-risk narratives [1] Company Introduction - Established in 2015 and headquartered in Suzhou, Jiangsu, Aishalon specializes in medical dressings and surgical infection control products, focusing on rehabilitation care and surgical infection control products [5] - The company primarily operates through OEM/ODM models, providing contract manufacturing services for large international medical device companies, with exports to North America, Europe, and South Korea [5] Product and Business Structure - Aishalon's main revenue comes from medical dressing products, particularly care pads, which constitute a significant portion of its overall income [6] - The company has established a comprehensive system covering R&D, production, and quality control, holding ISO 13485 certification and approvals from CE and the US FDA, ensuring stable access to international markets [10] - Aishalon has long-term partnerships with major international medical supply groups like Medline, resulting in stable order flows but also presenting a degree of customer concentration risk [10] Financial Performance - The company has shown steady operational performance, with both revenue and profit experiencing positive growth [11] - Revenue figures indicate a scale of approximately 600-700 million yuan, with continued growth expected post-2024, reflecting strong order and delivery stability [13] - Specific revenue data includes: - 2022: Approximately 573 million yuan - 2023: Approximately 619 million yuan - 2024: Approximately 703 million yuan - 2025 (Jan-Sep): 690 million yuan, a year-on-year increase of 42.84% [15] - Net profit figures are as follows: - 2022: 62.8 million yuan - 2023: 66.9 million yuan - 2024: 80.6 million yuan - 2025 (Jan-Sep): 49.4 million yuan [15][21] - The net profit margin has remained around 11%, indicating a relatively healthy profitability level among medical consumables companies, with profits primarily derived from core operations [16] - As of September 2025, total assets were approximately 1.279 billion yuan, with owner’s equity around 821 million yuan, maintaining a controllable debt ratio and a relatively stable financial structure [17] Industry Observation - Aishalon's listing highlights a path for non-"star innovative device" medical companies to capitalize in a rational capital market environment, providing a clear capitalization model [18] - The continuous entry of such companies into the Beijing Stock Exchange aids in transitioning the medical sector from "single-point innovation" to a coexistence of "multiple types of medical companies" [18] - The emphasis on stable operational capabilities is underscored as a scarce asset within the industry [18]

Group 1 - Aishalon Medical Technology Group Co., Ltd. has been listed on the Beijing Stock Exchange, marking it as the first new A-share listed company in Jiangsu Province for 2026 and the first in Suzhou's Xiangcheng District [1] - The company's stock price surged by 175.59% on its first trading day [1] - Aishalon specializes in the research, production, and sales of disposable medical consumables, focusing on rehabilitation care and surgical infection control [1] Group 2 - The company reported a revenue of 692 million yuan and a net profit of 80.71 million yuan for 2024, with projected revenue for 2025 expected to reach between 890 million and 940 million yuan, representing a year-on-year growth of 28.65% to 35.89% [1] - Aishalon holds 46 utility model patents, 10 design patents, 21 invention patents, and 2 copyrights, with 6 invention patents currently under review [1] - The company plans to use the funds raised from its public offering of 16.92 million shares at a price of 15.98 yuan per share to invest in the "Kaipule Public Health Medical Supplies Industrial Park Construction Project," which has a total investment of 670 million yuan [2]

Core Insights - Aishalon Medical Technology Group Co., Ltd. officially listed on the Beijing Stock Exchange on January 21, 2026, becoming the first A-share listed company in Jiangsu Province this year and the first in Suzhou's Xiangcheng District [2] - The company's stock opened with a significant increase of 224.78%, reaching a total market capitalization of 3.49 billion yuan [2] Company Overview - Aishalon Medical focuses on the research, production, and sales of disposable medical consumables in the fields of rehabilitation care and surgical infection control [3] - The company has established long-term strategic partnerships with several international medical device brands, including Medline Group from the U.S., Zarys Group from Poland, and Sejong Healthcare from South Korea [3] - Aishalon is recognized as the largest manufacturer of medical care pads in China, with annual output value exceeding 500 million yuan from 2022 to 2024, positioning itself among the top players in the domestic medical dressing industry [3] Financial Performance - From 2022 to 2024, Aishalon's operating revenue grew from 574 million yuan to 692 million yuan, while net profit increased from 63 million yuan to 81 million yuan, demonstrating a steady compound annual growth rate [4] - For the first nine months of 2025, the company achieved an operating revenue of 689 million yuan, a year-on-year increase of 42.84%, and a net profit of 73 million yuan, up 27.50% from the previous year [4] - The company has maintained a high proportion of overseas sales revenue, which reached 96.54% in the first half of 2025, indicating its strong role in the global supply chain [4] Industry Context - The medical dressing industry is characterized by rigid demand, driven by global aging populations, increasing surgical volumes, and heightened infection control awareness [5] - The market for medical dressings is expected to continue growing steadily, with a trend towards high-quality, multifunctional, and disposable products [5] Growth Strategy - Aishalon plans to use the funds raised from its IPO to invest in the "Kaipule Public Health Medical Supplies Industrial Park" project, aimed at expanding production capacity and developing new product lines [6] - The company is transitioning from a single dressing production focus to a broader medical consumables manufacturing and service platform, which is expected to reduce dependency on single products and clients [6] - Aishalon is also expanding its global production footprint, with existing bases in Thailand and plans for new facilities in Morocco, showcasing its strategic vision to adapt to international trade dynamics and cost pressures [6]

Core Viewpoint - The electronic sector in the A-share market has experienced a significant surge, with many stocks hitting the daily limit up, indicating strong investor interest and potential growth in this industry [1][6]. A-Share Market Performance - The A-share market showed an overall upward trend, with major indices rising to varying degrees. The ChiNext Index rose over 1.5%, and the Sci-Tech 50 Index increased by more than 4% [4]. - Specific indices and their performance include: - Shanghai Composite Index: 4120.10, up 0.16% [5] - Shenzhen Component Index: 14263.20, up 0.76% [5] - ChiNext Index: 3306.00, up 0.85% [5] Electronic Sector Highlights - The electronic sector led the market with a rise of over 2.8%, with several stocks reaching their daily limit up. Notable performers include: - Longxin Zhongke: 177.72, up 20% [7] - Zhongrong Electric: 143.40, up 20% [7] - Other stocks like Jiahua Technology and Jianghua Microelectronics also saw significant gains [6]. Lithium Mining Sector - The lithium mining sector experienced a substantial increase, with the sector rising over 2%. Stocks such as Dazhong Mining and Weicheng Mining hit their daily limit up. The rise was supported by a significant increase in domestic lithium carbonate futures, with the main contract rising over 6% [8]. New Stock Performance - A new stock, Aisheren, was listed today and saw a remarkable increase of over 200% during trading [12]. The company focuses on medical health, specializing in disposable medical supplies for rehabilitation and medical protection [13]. Hong Kong Market Activity - The Hong Kong market experienced low-level fluctuations, with the stock of Skyworth Group surging over 40% during trading, driven by positive news [2][16].

Core Viewpoint - Aisheren (BJ:920050) was listed on the Beijing Stock Exchange on January 21, with an opening increase of 224.78% and a total market capitalization of 3.49 billion yuan [2] Company Overview - Aisheren specializes in the research, production, and sales of disposable medical consumables used in professional rehabilitation care and medical protection [2] - The company's product range includes rehabilitation care products and surgical infection control products, offering items such as medical care pads, ice bags, surgical gowns, surgical drapes, and surgical kits [2] Financial Performance - Aisheren's total assets increased from approximately 837.99 million yuan in 2022 to about 1.20 billion yuan by June 30, 2025 [3] - Shareholder equity rose from approximately 607.31 million yuan in 2022 to about 795.19 million yuan by June 30, 2025 [3] - The company's revenue for the years 2022 to 2025 (first half) was reported as 574.66 million yuan, 575.00 million yuan, 691.64 million yuan, and 438.20 million yuan respectively [3] - Net profit figures for the same periods were approximately 62.80 million yuan, 66.94 million yuan, 80.61 million yuan, and 49.43 million yuan [3] Future Projections - For the fiscal year 2025, Aisheren expects revenue to be between 890 million yuan and 940 million yuan, representing a year-on-year growth of approximately 28.65% to 35.89% [4] - The projected net profit attributable to shareholders is estimated to be between 89.29 million yuan and 98.48 million yuan, with a growth rate of about 10.63% to 22.01% [4] - The company anticipates that its net profit after deducting non-recurring gains and losses will be between 86.11 million yuan and 95.29 million yuan, reflecting a growth of 19.37% to 32.11% [4] Customer Concentration - Aisheren's top five customers accounted for 81.99% to 88.40% of total sales revenue during the reporting periods, indicating a high level of customer concentration [4] - The largest customer, Medline Group, represented 71.51% to 77.73% of total sales revenue across the same periods [4] Sales Distribution - The majority of Aisheren's revenue comes from international sales, with overseas sales accounting for 90.99% to 96.54% of total revenue during the reporting periods [4] - The company's products are primarily sold in the United States, Europe, and South Korea [4] Ownership Structure - Prior to the IPO, Zhang Yong directly held 1.97% of the company's shares and indirectly controlled 79.58% through the controlling shareholder, Jiangsu Novick [5] - Zhang Yong, who is the chairman and general manager, has a total control of 88.69% of the company's shares [5]

Company Overview - The company specializes in medical dressings, focusing on two main categories, with over 70% of revenue coming from Medline Group[1] - Medline is the largest global manufacturer and distributor of surgical supplies, with an IPO raising approximately $6.264 billion to enhance its market presence[1] Financial Performance - Revenue growth is projected to accelerate, with 2024 revenue expected to increase by 20.4% year-on-year, reaching approximately 6.92 billion yuan[1] - Net profit for 2024 is anticipated to grow by 20.5% year-on-year, reaching around 0.81 billion yuan[1] Market Trends - The global low-value consumables market is expected to grow at a CAGR of 8.3% from 2024 to 2031, driven by factors such as aging population and rising chronic disease rates[1] - The domestic market for low-value consumables is projected to reach approximately 1280 billion yuan in 2023, with a CAGR of 14.8% from 2018 to 2023[1] Internationalization Strategy - The company is in a deepening phase of internationalization, focusing on core customer strategies and expanding production capacity overseas[1] - Key international clients include Medline, Zarys, and Sejong Healthcare, with a strong emphasis on maintaining high customer loyalty and competitive pricing[1] Risks - The company faces risks related to dependency on a single customer, fluctuations in raw material prices, and potential market competition intensification[1]